Efficacy and Safety of Bevacizumab Biosimilar FKB238 Versus Originator Bevacizumab: Results from AVANA, a Phase III Trial in Patients with Non-Squamous Non-Small-Cell Lung Cancer (non-sq-NSCLC)

BACKGROUND: Bevacizumab is an antiangiogenic recombinant humanized monoclonal antibody that inhibits tumor growth. FKB238, a bevacizumab biosimilar, has analytical pharmacokinetic and safety profiles similar to those of bevacizumab. OBJECTIVE: This phase III trial (NCT02810457) compared the efficacy...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:BioDrugs
Main Authors: Syrigos, Konstantinos, Abert, Istvan, Andric, Zoran, Bondarenko, Igor N, Dvorkin, Mikhail, Galic, Kristina, Galiulin, Rinat, Kuchava, Vladimer, Sriuranpong, Virote, Trukhin, Dmytro, Zhavrid, Edvard, Fu, Dongyue, Kassalow, Laurent M, Jones, Stephanie, Bashir, Zahid
Format: Artigo
Jezik:Inglês
Izdano: Springer International Publishing 2021
Teme:
Original Research Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC8295151/
https://ncbi.nlm.nih.gov/pubmed/34264503
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40259-021-00489-4
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki